d-nome funding: Synthetic biology startup D-Nome raises $1.5 million in funding from Ankur Capital, Campus Fund

Synthetic biology startup D-Nome raised $1.5 million in seed funding from Ankur Capital, Campus Fund, and different buyers.

D-Nome intends to democratise molecular diagnostics with their deviceless PCR tech.

Began in July 2021 by PhD college students – Divya Sriram and Sujoy Deb – from Telanaga-based The Centre of Mobile and Molecular Biology, the startup’s focus is to construct fast point-of-care diagnostics for human infectious illnesses and different functions utilizing genomics and artificial biology.

“Our mission is to fill the hole in testing and allow personalised drugs at scale, one thing that has not been profitable because of the lack of scalable and correct diagnostic instruments. We hope to create important impression socially and economically for growing nations and pave the best way for next-generation healthcare relying closely on genomics,”

At present, there are three most important strategies of testing – routine tradition which is time consuming and requires infrastructure, fast antigen/ antibody checks that are faster however lack accuracy, and PCR/ Actual time PCR (RT-PCR) checks which is the gold commonplace for accuracy however is dear and wishes expert labour.

Keep on prime of technology and startup news that issues. Subscribe to our every day e-newsletter for the newest and must-read tech information, delivered straight to your inbox.